$GH

Kalia Kumud sold $445K of GH

Kalia Kumud (Chief Information Officer) sold 3,418 shares of Guardant Health, Inc. (GH) at $130.24 ($0.45M total) on 2026-06-11.

Original reporting
SEC EDGAR · Kalia Kumud
Published Jun 15, 2026, 10:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may monitor insider activity for sentiment, but the text contains no operational, regulatory, or financial catalyst.

03

What to watch

Insider sales often reflect diversification, taxes, or liquidity needs; the article provides no size-vs-ownership context beyond post-transaction holdings.

Relevance 4/10Novelty 5/10Timing: SEC Form 4 filed 2026-06-15 for a 2026-06-11 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health CIO Kalia Kumud filed an SEC Form 4 selling 3,418 shares at $130.2386 on 2026-06-11.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan stated and no accompanying fundamental catalyst in the text.

Market effects

No sector-level read-across provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Because the sale is not explicitly tied to a 10b5-1 plan in the filing text, some traders may treat it as a stronger near-term bearish signal than a typical planned sale.

Key entities

  • Guardant Health, Inc.

    Subject of the SEC Form 4 insider transaction; officer sale disclosed.

  • Kalia Kumud

    Chief Information Officer who sold 3,418 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.